COMMUNIQUÉS West-GlobeNewswire

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017
06/06/2017
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Ossur Hf : Transactions in relation to share buyback program
06/06/2017
Announcement from Össur hf. No. 43/2017 Reykjavík, 05 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Issuance of new shares to the Finnish Innovation Fund Sitra pursuant to the financing arrangement announced on 21 July 2016
06/06/2017
Company announcement, Helsinki, 6 June 2017 at 7:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]
MITHRA SIGNS EXCLUSIVE AGREEMENT FOR TIBELIA® IN CANADA
06/06/2017
PRESS RELEASE Mithra signs Exclusive agreement for Tibelia® in Canada Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada Marketing authorization process is ongoing Tibelia® already [...]
Refixia® (nonacog beta pegol; N9-GP) approved in the EU
06/06/2017
Company Announcement No 42/2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting
06/06/2017
Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefing on Saturday, June 10 from 2 - 4 p.m. PDT DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in medical technology, today [...]
Medtronic SureTune(TM)3 Receives Health Canada Licence for Deep Brain Stimulation Therapy
06/06/2017
DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology [...]
AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
06/06/2017
AbCellera announces a project with Sanofi Pasteur to apply its human antibody discovery and immune profiling technology for the research and development of next-generation influenza vaccines. VANCOUVER, British Columbia [...]
Annual General Meeting held
06/06/2017
Navamedic ASA has today, 6 June 2017, held an annual general meeting. All resolutions were made in accordance with the board's/nomination committee's proposals. The minutes from the general meeting is attached hereto [...]
Novo Nordisk A/S - Share repurchase programme
06/06/2017
Bagsværd, Denmark, 06 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada
06/06/2017
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi ® (palonosetron hydrochloride) in Canada Lugano, Switzerland and Pickering, Canada, June 6, 2017 - [...]
Verona Pharma plc : Holding(s) in Company
06/06/2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please [...]
uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
06/06/2017
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Steven L. Zelenkofske, D.O., as Chief [...]
Verona Pharma plc : Holding(s) in Company
06/06/2017
For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting [...]
Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017
06/06/2017
Heidelberg, Germany, June 6, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Company [...]
Helsinn: First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Dr Sarah A Buckley
06/06/2017
First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington Lugano, Switzerland, [...]
Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for Prediction of Acute Kidney Injury Cleared, Available in Europe
06/06/2017
New test expands Ortho's VITROS(R) menu RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the [...]
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
06/06/2017
Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel [...]
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
06/06/2017
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna [...]

Pages